DK2608806T3 - Epstein-barr-virusvaccine - Google Patents
Epstein-barr-virusvaccineInfo
- Publication number
- DK2608806T3 DK2608806T3 DK11751867.0T DK11751867T DK2608806T3 DK 2608806 T3 DK2608806 T3 DK 2608806T3 DK 11751867 T DK11751867 T DK 11751867T DK 2608806 T3 DK2608806 T3 DK 2608806T3
- Authority
- DK
- Denmark
- Prior art keywords
- particle
- ebv
- vaccine
- epstein
- barr virus
- Prior art date
Links
- 241000701044 Human gammaherpesvirus 4 Species 0.000 title abstract 8
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000002245 particle Substances 0.000 abstract 8
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 3
- 230000009466 transformation Effects 0.000 abstract 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000002101 lytic effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16223—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16251—Methods of production or purification of viral material
- C12N2710/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16261—Methods of inactivation or attenuation
- C12N2710/16262—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16271—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37702710P | 2010-08-25 | 2010-08-25 | |
| EP10008835 | 2010-08-25 | ||
| PCT/EP2011/064672 WO2012025603A1 (en) | 2010-08-25 | 2011-08-25 | An epstein-barr-virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2608806T3 true DK2608806T3 (da) | 2018-01-29 |
Family
ID=43478663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11751867.0T DK2608806T3 (da) | 2010-08-25 | 2011-08-25 | Epstein-barr-virusvaccine |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140227305A1 (da) |
| EP (1) | EP2608806B1 (da) |
| JP (1) | JP2013541507A (da) |
| CN (1) | CN103328003A (da) |
| DK (1) | DK2608806T3 (da) |
| ES (1) | ES2655535T3 (da) |
| WO (1) | WO2012025603A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013098364A1 (en) | 2011-12-30 | 2013-07-04 | Deutsches Krebsforschungszentrum | Second generation virus-like particles (vlp) from epstein-barr viruses for vaccination purposes |
| DE102012105193B4 (de) * | 2012-06-15 | 2014-04-03 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Stimulation der zellulären Immunantwort gegen das Epstein-Barr-Virus (EBV) |
| EP3013789B1 (en) | 2013-06-28 | 2020-03-04 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| RU2017126206A (ru) | 2014-12-23 | 2019-01-25 | Маргарет Анне БРИМБЛЕ | Аминокислотные и пептидные конъюгаты и направления их использования |
| US10314906B2 (en) | 2015-03-18 | 2019-06-11 | University Of Massachusetts | Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease |
| AU2017223267B2 (en) | 2016-02-26 | 2021-07-22 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| WO2017148928A1 (en) * | 2016-03-01 | 2017-09-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Means and methods for treating herpesvirus infection |
| EP3320917A1 (en) | 2016-11-10 | 2018-05-16 | Deutsches Krebsforschungszentrum | Improved ebv vaccine |
| EP3773708A2 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic epstein barr virus polypeptides |
| WO2020074708A1 (en) * | 2018-10-12 | 2020-04-16 | Deutsches Krebsforschungszentrum | Epstein-barr virus-like particles with broadened antigenic spectrum |
| US20210398689A1 (en) * | 2020-06-23 | 2021-12-23 | Corsight.Ai | Autonomous mapping and monitoring potential infection events |
| CN111620955B (zh) * | 2020-07-01 | 2022-11-08 | 北京康爱瑞浩细胞技术有限公司 | 一种多靶位复合抗原及其应用 |
| WO2022073234A1 (zh) * | 2020-10-10 | 2022-04-14 | 中山大学肿瘤防治中心 | 一种抑制eb病毒的肽和编码该肽的dna及其应用 |
| WO2022084373A1 (en) | 2020-10-20 | 2022-04-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | METHOD FOR MANUFACTURING HEK293 CELL LINE, METHOD FOR MANUFACTURING EB-VLPs AND COMPOSITION COMPRISING SAID EB-VLPs |
| EP4232076A1 (en) | 2020-10-20 | 2023-08-30 | The Chancellor, Masters and Scholars of The University of Oxford | Methods and compositions for treating epstein barr virus-associated cancer |
| CN114657191B (zh) * | 2022-02-18 | 2023-08-01 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种EBNA3A截短mRNA相关疫苗及其制备方法和应用 |
| WO2025209940A1 (en) | 2024-03-31 | 2025-10-09 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Ebv vaccine and antibodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070196389A1 (en) * | 2005-11-18 | 2007-08-23 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
| EP2065462A1 (en) * | 2007-11-27 | 2009-06-03 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens |
| WO2010062757A1 (en) * | 2008-11-03 | 2010-06-03 | Ligocyte Pharmaceuticals, Inc. | Improved methods for isolating enveloped virus-based vlps free of infectious agents |
-
2011
- 2011-08-25 US US13/818,711 patent/US20140227305A1/en not_active Abandoned
- 2011-08-25 JP JP2013525312A patent/JP2013541507A/ja active Pending
- 2011-08-25 EP EP11751867.0A patent/EP2608806B1/en active Active
- 2011-08-25 CN CN2011800511355A patent/CN103328003A/zh active Pending
- 2011-08-25 ES ES11751867.0T patent/ES2655535T3/es active Active
- 2011-08-25 WO PCT/EP2011/064672 patent/WO2012025603A1/en not_active Ceased
- 2011-08-25 DK DK11751867.0T patent/DK2608806T3/da active
-
2016
- 2016-03-22 US US15/077,477 patent/US10300129B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012025603A1 (en) | 2012-03-01 |
| US10300129B2 (en) | 2019-05-28 |
| US20160296618A1 (en) | 2016-10-13 |
| ES2655535T3 (es) | 2018-02-20 |
| EP2608806A1 (en) | 2013-07-03 |
| US20140227305A1 (en) | 2014-08-14 |
| CN103328003A (zh) | 2013-09-25 |
| JP2013541507A (ja) | 2013-11-14 |
| EP2608806B1 (en) | 2017-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2608806T3 (da) | Epstein-barr-virusvaccine | |
| CY1122654T1 (el) | Ενωσεις για βελτιωμενη iiκη μεταγωγη | |
| CY1118138T1 (el) | Ιοσωματιο απελευθερουμενο μετα απο μολυνση κυτταρων θηλαστικων απο ανθρωπινο κυτταρομεγαλοϊο (hcmv) το οποιο περιεχει μια πρωτεϊνη συντηξης και χρηση αυτου | |
| EP2614140B8 (en) | Mdck-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells | |
| MX2015005505A (es) | Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano. | |
| NZ712943A (en) | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels | |
| WO2011109833A3 (en) | Induced dendritic cell compositions and uses thereof | |
| WO2013142324A8 (en) | Neutralizing antibodies to hiv-1 and their use | |
| WO2013070776A8 (en) | Neutralizing gp41 antibodies and their use | |
| MX2010003713A (es) | Vacunas de citomegalovirus y metodos de produccion. | |
| IL251338B (en) | Plant cells and extract comprising virus like particles comprising chimeric viral proteins and composition thereof | |
| SG10201407519TA (en) | Method For Producing T Cell Receptor-Like Monoclonal Antibodies And Uses Thereof | |
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| MX387666B (es) | Composiciones y su uso en el tratamiento de citomegalovirus | |
| GB2513768A (en) | Complexes of cytomegalovirus proteins | |
| MX359903B (es) | Proteínas estructurales de una mutación del parvovirus como vacunas. | |
| PH12015500499A1 (en) | Recombinant measles virus expressing chikungunya virus polypeptides and their applications | |
| WO2011137354A3 (en) | Delivery proteins | |
| WO2013096866A3 (en) | Processes using vlps with capsids resistant to hydrolases | |
| TR201904215T4 (tr) | Bakteriyel yapay kromozomlar. | |
| CA2863981A1 (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses | |
| WO2010118205A3 (en) | Production of an intact virus in a mammalian (non-host) cell system using a secondary non-host viral construct | |
| WO2011112601A3 (en) | Continuous flow bioreactor for magnetically stabilized three-dimensional tissue culture | |
| HK1210475A1 (en) | Herpes simplex virus vaccine | |
| WO2011057254A3 (en) | Simian adenoviral vector-based vaccines |